Very small island
POPULARITY
11 episodes with Islet
5 episodes with Islet
6 episodes with Islet
6 episodes with Islet
2 episodes with Islet
4 episodes with Islet
3 episodes with Islet
7 episodes with Islet
2 episodes with Islet
3 episodes with Islet
3 episodes with Islet
2 episodes with Islet
2 episodes with Islet
2 episodes with Islet
7 episodes with Islet
6 episodes with Islet
5 episodes with Islet
2 episodes with Islet
In this episode, we review the high-yield topic of Islet Cell Tumors from the Gastrointestinal section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with Steven Russell, MD, PhD, Chief Medical Officer at Beta Bionics, to discuss the latest real-world outcomes from the iLet Bionic Pancreas—an autonomous insulin delivery (AID) system cleared by the US Food and Drug Administration (FDA) in 2023. Russell outlines the iLet's fully automated design, which sets it apart from conventional AID systems by requiring no manual settings, carb ratios, or correction factors. The system determines 100% of insulin dosing, adapting continuously to glycemic trends without relying on user engagement. This autonomy makes the iLet particularly effective for individuals with suboptimal diabetes self-management or limited access to endocrinology care. New real-world data, covering 3,300 users from the first year of commercial rollout, reveal a mean baseline A1c of 8.5%—higher than the 7.8% in the pivotal trial and reflective of the broader U.S. type 1 diabetes (T1D) population. The iLet reduced glucose management indicator to 7.3%, yielding an average A1c reduction of 1.2%, more than double that seen in the pivotal study. Outcomes were most pronounced among those with severe hyperglycemia: users starting with A1c >14% saw average reductions of 7%, with low rates of diabetic ketoacidosis (DKA) and minimal increases in hypoglycemia (median time
Yi-Chun Chen is taking a close-up look at some of the body's hardest-working cells — the ones often processing an overabundance of modern-day food and nutrients. “From an evolutionary point of view, our cells are not designed to deal with that,” said Dr. Chen, who joined the department of Anatomy, Physiology, and Pharmacology at the University of Saskatchewan last year as an assistant professor. She said our bodies are pushed into churning out large amounts of insulin rapidly after snacks and meals, “which makes the beta cells work extra hard.” Raised in Taiwan and inspired by her grandfather—a retired elementary school science teacher—Chen's fascination with biology first led her to work as a medical laboratory technologist, then to the world of cellular research. Using both rodent and human models, Chen is studying pancreatic beta cells: the way they process peptide hormones like insulin and how their behaviour and function is affected by an excess of nutrients. Using high-resolution imaging, she and her team are examining how both humans and mice synthesize, process, and clear peptide hormones. “There are a lot of things we still don't know about peptide hormones, not just in the pancreas, but in the brain, in the gut,” she said. “Those are fascinating.” Last year, Chen was the recipient of a Canadian Institutes of Health Research Early Career Transition Award. After moving from UBC to Saskatchewan, Dr. Chen said she's thankful to see so much support already from her established and mid-career prairie colleagues. “They can mentor us and guide us, and we also have a group of five or six young scientists,” she said. “I can envision myself working on many, many interesting projects with them.” Her goal today is to identify biomarkers that could predict diabetes far earlier. She hopes to develop biochemical assays that measure proinsulin levels to serve as an early warning system. This could enable interventions months or even years before a traditional diagnosis based on blood glucose levels. “We want to be able to predict the development of, for example, type 1 or type 2 diabetes before they are diagnosed,” said Chen. In the long term, Chen envisions both preventative strategies and regenerative therapies to fight diabetes. Stem cell-derived beta cells may be a future solution, she said. “We are making really good progress in Canada, actually. We have clinical trials. We're putting the stem cell–derived beta cells into patients with type 1 diabetes.” She hopes this will one day reduce the need for constant insulin injections, even helping curb obesity. “Don't give up,” Chen said. “We are passionate and we want to work on many, many things.” “If you like it, keep going.”
As part of the government's commitment to delivering accessible, high-quality medical services, the Permanent Secretary in the Ministry of Health, Wellness and Elderly Affairs, Jenny Daniel, recently conducted an official visit to evaluate the progress of the ongoing enhancements and rehabilitative works at the Gros-Islet Polyclinic. The comprehensive upgrade project is designed to expand the clinic's service capabilities, improve patient care, and create a more efficient and comfortable environment for both staff and the public. One of the key enhancements includes the extension of operational hours to provide round-the-clock medical services.
This is poewks podcast, the very supernatural podcast hosted by poewk! Most poewk don't like organs and want to talk so this poewk (me) has done that!!! This podcast is being held by issac Marshall and helping me is Adam freeman. We hope the show goes on to be as famous as The MSM Project (listen to it btw it's what inspired me so do this) Hosted on Acast. See acast.com/privacy for more information.
With a symbolic sod-turning ceremony at the Gros Islet Polyclinic, the Ministry of Health, Wellness & Elderly Affairs has officially launched critical infrastructural upgrades as part of its commitment to achieving Universal Health Coverage (UHC) in Saint Lucia. This initiative marks a major step in transforming the facility into a 24-hour operation, ensuring that residents have continuous access to essential healthcare services. The planned improvements include the expansion and modernization of the Accident & Emergency Unit, allowing for faster and more efficient patient care. Additionally, new doctors' offices will be introduced to increase consultation spaces, ensuring a more effective patient flow. The upgrades will also feature a dedicated staff lounge to enhance the comfort and well-being of healthcare professionals.
With a symbolic sod-turning ceremony at the Gros-Islet Polyclinic, the Ministry of Health, Wellness & Elderly Affairs has officially launched critical infrastructure upgrades as part of its commitment to achieving Universal Health Coverage (UHC) in Saint Lucia. This initiative marks a major step in transforming the facility into a 24-hour operation, ensuring that residents have continuous access to essential healthcare services. The planned improvements include the expansion and modernization of the Accident & Emergency Unit, allowing for faster and more efficient patient care. Additionally, new doctors' offices will be introduced to increase consultation spaces, ensuring a more effective patient flow. During this period, all healthcare services at the facility will remain fully operational. The Ministry acknowledges that there may be temporary inconveniences, including noise and restricted access to certain areas, and appreciates the public's patience and cooperation as these necessary upgrades take place.
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Welcome to this special edition of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosted by Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center. Included as part of the HCPLive This Year in Medicine series, this episode recaps headlines and practice updates related to continuous glucose monitoring (CGM) from the past year, with a focus on regulatory news from Medtronic, Dexcom, Abbott, and Senseonics. In recognition of the 25th anniversary of the first US Food and Drug Administration (FDA) approval of a CGM device in 1999, hosts also provide historic context for each company spotlighted during the episode. Medtronic To begin the episode, hosts start where the journey began: the FDA approval of the MiniMed in June 1999. In the 25 years since, MiniMed was acquired by Medtronic but has continued to remain among the leaders in CGM technology. During their conversation, hosts spend time discussing early experiences with CGM as well as newer advances from Medtronic, including the 2024 approval of the Simplera CGM. Dexcom Conversation around Dexcom ranges from the company's STS sensor in 2006 to the current G7 model as well as integration with pumps like the OmniPod 5, T:slim X2, and the Islet. When discussing news from 2024 from Dexcom, hosts call attention to the partnership with the Oura Ring and the launch of Stelo, the first FDA-approved over-the-counter CGM. Abbott Next, hosts dive into advancements from Abbott—starting with the Navigator and advancing to the Libre, including the Libre 3 plus, which features real-time data and 15-day wear. The hosts also celebrate Abbott's collaborations with Tidepool and major insulin pump manufacturers as well as the FDA clearance of the Lingo and Libre Rio. Senseonics The episode concludes with a discussion of Senseonics' Eversense CGM, the only FDA-approved implantable CGM. As the hosts highlight, Eversense has progressed over the years from a 90-day sensor to the groundbreaking 365-day wear system, which received approval in 2024. The hosts also highlight the potential of future developments, such as eliminating the external transmitter for a fully implantable design. Key Timestamps 00:00 - Start 01:37 - 25 Years of CGM 02:20 - Medtronic CGM History & Updates 05:01 - Dexcom CGM History & Updates 10:06 - Abbott CGM History & Updates 15:48 - Eversense CGM History & Updates
Join our scientific team in the discussion of the 3 most clinically impactful papers of the month, the crème de la crème of our weekly top picks. This month we're discussing: Risk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging. A Systematic Review and Meta-Analysis https://jamanetwork.com/journals/jama/article-abstract/2823869 The Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients with Heart Failure: An Analysis of the DETERMINE Trials https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.124.012349 Islet-after-kidney Transplantation versus Kidney Alone in Kidney Transplant Recipients with Type 1 Diabetes (KAIAK): a Population-based Target Trial Emulation in France https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00241-9/abstract Scientific team: Ricardo Ladeiras Lopes, Mário Santos and João Sérgio Neves Discover Medical Portfolio App weekly top picks - the latest and most relevant papers, curated by our team of experts! https://linktr.ee/medicalportfolioapp
Fall festival season continues with a trip to the Southern Adirondack Wool & Arts Festival to meet the men behind two new yarn companies.
The Gros Islet Reunion 2024 has taken a unique turn this year by incorporating a comprehensive Health Fair, highlighting the vital role of health and wellness in strengthening community ties and fostering healthier communities. Organized in collaboration with the Ministry of Health, Wellness, and Elderly Affairs, the event drew a significant number of residents from Gros Islet and the neighboring communities, making it a cornerstone of this year's reunion festivities. Candy Sextius, Family Life Educator at the Ministry of Health, Wellness and Elderly Affairs, shared her enthusiasm about the initiative, "The Gros Islet reunion committee reached out with a vibrant plan to reunite folks from the diaspora through a month-long series of activities. Our participation in this event provided a unique opportunity to showcase the extensive services offered by the Ministry." Read more: https://www.govt.lc/news/ministry-of-health-promotes-wellness-at-the-2024-gros-islet-reunion-fair
Islet Cell Replacement Therapy – Featuring Manasi Jaiman, MD, MPH, Pediatric Endocrinologist and Diabetes Researcher with expertise in both drug and device developments in type 1 diabetes.TAKING CONTROL OF YOUR DIABETES® - THE PODCAST! ...With Expert Endocrinologists Living with T1D, Drs. Steven V. Edelman & Jeremy PettusIslet cell replacement therapy represents a promising advancement to cure type 1 diabetes. In this episode of the Taking Control of Your Diabetes podcast, our special guest, Dr. Manasi Jaiman, MD, MPH, a leading pediatric endocrinologist and diabetes researcher, joins hosts Dr. Jeremy Pettus and Dr. Steve Edelman to delve into the intricacies of stem cell research and its potential to transform diabetes treatments. Dr. Manasi Jaiman discusses her journey into diabetes research, the significance of islet and beta cells, and the advancements in programming stem cells for therapeutic purposes. She also explains the current methods for delivering these designed cells to patients, the importance of immunosuppression in cell therapy, and the progress made in encapsulation techniques. In this episode, we will talk about:The role of beta and islet cells in glucagon productionHow close we are to a cure for type 1 diabetesThe sources of islet cells and their importanceDifferent types of stem cells and their applicationsHow new stem cells are delivered to diabetes patientsThe importance of immunosuppression in cell therapyRecent advancements in cell therapy, including cell infusion and encapsulationThe challenges and timelines in finding a cure for type 1 diabetesHow to find and participate in clinical trials for diabetesThe importance of volunteering in clinical research**Tune in for 2 new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!** ★ Support this podcast ★
Can islet cell transplant eliminate the need for insulin in patients with type 1 diabetes? Find out about this and more in today's PeerDirect Medical News Podcast.
Il percorso delle Cer, le Comunità Energetiche Rinnovabili, appare ancora in una fase embrionale. I progetti non mancano, così come gli incentivi, ma i due anni di attesa per conoscere le regole stabilite da decreti attuativi ha rallentato fortemente il processo. Secondo dati del GSE; a giugno 2023 sono solo 35 le Cer attive in Italia che hanno richiesto l'accesso agli incentivi. In Campania dove è attiva la prima Cer solidale, a Napoli, nel quartiere di Napoli est, San Giovanni a Teduccio, è in fase di definizione lo statuto della prima esperienza nazionale di Cer all'interno di un'area Asi, che per ora sarà composta da sette aziende. La regione spinge l'acceleratore sui piccoli comuni pensando alla riapertura del bando che permette di ottenere 8mila euro per la promozione delle Comunità rinnovabili. Un mese fa è stata avviata l'attività prevista per il progetto europeo ISLET, che studia e promuove la realizzazione di comunità energetiche nelle piccole isole del Mediterraneo. Procida è l'unica piccola isola italiana a partecipare. Lungo il percorso si dovranno risolvere e superare diverse criticità di un sistema complesso e ancora poco conosciuto: dalla formazione del gruppo che realizza la Comunità, all'immissione in rete dell'energia prodotta e al riconoscimento degli incentivi, fino alla difficoltà di trovare siti in cui installate gli impianti.
The vibrant town of Gros Islet is set to come alive with celebrations as the Gros Islet Reunion 2024 Committee, in collaboration with the Ministry of Equity, Social Justice and Empowerment and the Folk Research Centre (FRC), present ‘Listwa Gwozilay'. This gathering aims to document and celebrate the rich cultural history of the northern town, offering locals and overseas residents a unique opportunity to connect with their roots and share cherished memories. David Moise, Social Transformation Officer for Gros-Islet, expressed his enthusiasm for the event, stating, "In July 2024, we are welcoming both local and overseas residents of Gros-Islet to the town. We will be hosting a Gros Islet reunion in 2024, and one of the activities that I have a keen interest in; the 'Listwa Gwozilay'. The intention is to try documenting the history of the Gros Islet Town, to hear how things happened a long time ago, how people lived, and what they were engaged in, especially the economic activities, to have this documented." "Listwa Gwozilay" is an opportunity for older generations to reminisce and serves as a learning platform for the youth and a stimulating point of discussion for the diaspora community. Attendees can expect a dynamic agenda featuring screenings of insightful interviews, engaging panel discussions, and an open forum for community dialogue. Additionally, live entertainment will be provided, adding to the festive atmosphere of the evening. “It is an activity for not only our older folks but the youth as well. We also see this as an opportunity for those in the diaspora to relive some of the memories they left behind,” noted Moise. As part of the ongoing efforts to preserve, share, and celebrate the cultural heritage of Gros Islet, the "Listwa Gwozilay" event promises to be a memorable occasion for all who attend. The event is scheduled for Tuesday, July 23rd, 2024, from 6:30 p.m. to 9:00 p.m. at the Monchy Human Resource Centre.
Are you interested in learning more about T1D islet stem cells transplants? Dr. Meiying Zhuang, an esteemed Endocrinologist at BC Diabetes, will be sharing information about the potential of stem cell therapy, ongoing research studies, and how you can get involved in this groundbreaking research!
In this interview, I'm humbled to be joined by Lindy-Fay Hella of both Wardruna and Dei Farne to talk about her new album “Islet”, her undying love for Depeche Mode, and the mysteries of the sea. Thank you for joining, Lindy. As a long time fan, you have no idea how starstruck I am by the opportunity to chat with you about your music and our shared love of birds. Patreon.com/nordicsoundchannelMedium.com/@nordicsoundchannelSupport the show
Today we're tackling a question we hear all the time: How do you tell Type 1 and Type 2 diabetes apart? We'll break it down by discussing their unique causes, symptoms, and treatments. Plus, we share the different diagnostic tests doctors use, ranging from basic blood sugar checks to specialized autoimmune tests for Type 1. Ever heard of Type 1.5 (LADA)? We will discuss the nuances behind Type 1.5 and treatment and more! In This Episode We'll Cover: The differences between Type 1 and Type 2 diabetes Causes, symptoms, and treatments for Type 1 and Type 2 diabetes Diagnostic methods for Type 1 and Type 2 How autoimmune testing is used to detect specific antibodies targeting the pancreas for Type 1 What Type 1.5 Diabetes is and its treatment The different treatment approaches for Type 1, such as insulin therapy, a balanced diet, exercise, and blood sugar monitoring The different treatment strategies for Type 2, including focusing on lifestyle changes, oral or injectable medications, and potential insulin therapy + MUCH MORE! Our 2 simple asks to help us continue a free weekly show: Rate on iTunes or Spotify - it literally takes two seconds Review - if you love the show, please leave a review on iTunes For additional resources and shownotes, visit https://diabetesdigital.co/category/podcast/ Jenny's Podcast Episode: How I Navigate Type 1 Diabetes as a Registered Dietitian How to Know When it's Time to Start Insulin Tests to confirm Type 1:These tests confirm the autoimmune basis of Type 1 diabetes by assessing specific antibodies associated with the condition. These include Islet cell cytoplasmic autoantibodies (ICA), Glutamic acid decarboxylase autoantibodies (GADA), Insulinoma-associated-2 autoantibodies (IA-2A), and Insulin autoantibodies (IAA). Elevated levels of these antibodies indicate a higher likelihood of Type 1 diabetes. Supplementary evaluations, such as a C-peptide test or an insulin assay test, may accompany the diabetes antibody panel to provide a more thorough assessment of the diabetes status. These tests, combined with the diabetes antibody panel, offer a comprehensive overview of the condition. Interpretation of test results involves understanding that positive findings suggest the presence of antibodies associated with Type 1 diabetes or an increased risk of developing it. Conversely, negative results may indicate a lower probability of Type 1 diabetes, although some individuals with the condition may not exhibit these antibodies. It's essential to consult with a healthcare provider to grasp the implications of test outcomes for your specific circumstances.
Venus de notre univers, Sébastien & Simon vous présentent les nouveaux jeux de société de la semaine comme toujours en 1h30 seulement ! ______________________________________
https://www.facebook.com/lindyfayhellaofficial/photos https://lindy-fayhella.bandcamp.com/album/hildring --- Support this podcast: https://podcasters.spotify.com/pod/show/shawn-ratches/support
It's the “season finale” of series 5! Join PICTISH TRAIL and LAURA for another hour of LOST MAP goodness, including a sneaky peek at all the new music we're releasing through our POSTMAP CLUB. We've got the first single from a fresh signing called AFTERLANDS; a live session track from MARTHA FFION; and a taste of the forthcoming album from SAVAGE MANSION. We've also got information on our December events in London and Edinburgh, as well as an archive track from the mad-cap musical inventor, ICHI.Our featured interview this month is with Roxy Brennan, aka TWO WHITE CRANES, who talks us through her life in music, the various scenes she's been a part of in Bristol, Oxford and Brighton, as well as a deep dive on her brand new album - Self Build - which is out NOW on limited edition CD.There's also a special edition of FIRST GIG WORST GIG, featuring Emma Daman Thomas from the band ISLET - who reports on her tween BritPop fantasies, and reveals the perils of early-00's fashion for drummers. ISLET will be performing at our HUMBUG! all-dayer at SUMMERHALL in EDINBURGH on Saturday 16th December.To support what we do at Lost Map, you should join our membership club - PostMap Club! Membership starts at just £3, and you'll receive printed postcards delivered to your door every month, containing download codes for new music from the label. You'll receive a badge, too - as well as a newsletter and a discount of 15% on all records, CDs, tapes and other merch in our webshop. Digital & gift memberships are also available. Visit lostmap.com/club for details on how to join.NEW MEMBERS (including Gift Subscriptions) during December 2023, will receive a bumper pack of postcards + TEN YEARS OF LOST MAP, a brand new double CD containing 44 of our best tracks from the last decade!-EPISODE TRACKLISTING: 1. Afterlands - ‘I Woke To The Sound Of The Wind'2. Martha Ffion - 'What They Said About You' Live Session (clip)3. Savage Mansion - 'Present Tense' (clip)4. Two White Cranes - Clips from Self Build5. Two White Cranes - 'Sandstone'6. Islet - 'Sherry'7. Ichi - 'Hippo + 47'- SOME SERIOUSLY USEFUL LINKS: Join PostMap Club: lostmap.com/clubTwo White Cranes - Self BuildLost Map presents Weird Wave @ The Lexington, London - 8th DecDaylight Music w/ Lost Map @ St Johns on Bethnal Green - 9th DecHUMBUG! - EDINBURGH - 16th DecSavage Mansion - The Shakes (pre-order)Caps and T-shirtsNew records from Lost MapIf you'd like to get in touch with us, plop us an email: club@lostmap.comThis episode of the Lost Map Podcast was presented by Pictish Trail and Laura Doherty, edited and with additional production from Joe Cormack.
The Rotary Club of Gros-Islet, in collaboration with the Ministry of Equity, Social Justice, and Empowerment, is pleased to announce the commencement of a Parent Enrichment Programme in the northern town of Gros-Islet. The programme started off on November 21, 2023, at the Gros-Islet Human Resource Centre. The training will be held every Tuesday and Thursday for the next three weeks, from 5 PM to 7 PM. The participants, meticulously identified by the Social Transformation Officers (STO), Welfare Officer, and Family Case Worker, represent a diverse group committed to enhancing their parenting skills
Take your binoculars or take a picnic basket, either way this is a scenic and historic place to sit back in a classic adirondak chair. Graeme and Dave explain how they found it, and where you can too!
This is Dice Tower Now for the week of October 17, 2023. This week, top prizes go to the unknown planet, 7 Wonders earns a medal, Tom Lehmann admits winter is coming, and an epic designer makes fishy preserves. TOP STORIES (1:55) Essen Spiel reports numbers as biggest ever Planet Unknown wins Deutscher Spiele Preis Dune: Imperium Uprising invitational tournament Winter Court by Tom Lehmann 7 Wonders: Architects Medals expansion Koinobori by designer David Bernal and Perro Loko Games Salton Sea from designer David Bernal, published by Devir Evil Corp by designer Jérémy Ducret and La Boîte de Jeu Alpenglow by designer Sean Wittmeyer and Waterworks Games Epochs: Course of Culture coming from publisher ICE Makes Coral successor Islet from 2Tomatoes Games and designer Thomas Dagenais-Lespérance Conservas by Scott Almes and Salt and Pepper Games Manifest Destiny by designers Jay Cormier and Sen-Foong Lim Cryptid Cafe: Chefs Apprentice from Devon Mettlin and Squatchy Games CROWDFUNDING (14:25) Kavango The Night Cage Shrieking Hollow Aberration Forage Cretaceous Rails Diatoms SPONSOR UPDATE (24:10) The Lucky Duck booth at Essen THE HOTNESS (26:30) Moon Heat: Pedal to the Metal Dune: Imperium – Uprising Kutná Hora: The City of Silver Voidfall Evacuation Nucleum Ancient Knowledge The White Castle Space Marine: The Board Game CONNECT: Follow our Twitter newsfeed: twitter.com/dicetowernow Dig in with Corey at DiceTowerDish.com.
In this episode we sit down with Dr. Melena Bellin to discuss chronic pancreatitis. We discover its symptoms, risk factors, its connection to diabetes as well as Islet transplantation. Dr. Melena Bellin is a physician and Professor of Pediatric Endocrinology at the University of Minnesota and the University of Minnesota Masonic Children's Hospital. She has an active clinical research program focused on diabetes and pancreatitis. She serves on the board of directors for the National Pancreas Foundation and on the council for the American Pancreatic Association. In This Episode You Will Learn The Functions of the Pancreas What Is Chronic Pancreatitis vs Acute Pancreatitis Symptoms and Risk Factors of Chronic Pancreatitis Chronic Pancreatitis' Effect on Digestion How Chronic Pancreatitis Can Lead to Diabetes Islet Transportation and Other Treatments Connect with Yumlish: Website Instagram Twitter Facebook LinkedIn YouTube Connect with Dr. Melena Bellin: Website “Healthy Family Recipes For Pancreas Disease” Cookbook Email National Pancreas Foundation --- Send in a voice message: https://podcasters.spotify.com/pod/show/yumlish/message
Maed in India's illustrator and graphic designer Alika is back with another Maed Mixtape. As with her last mixtape ‘Hippocampus', she chose the name because she really wanted to draw an islet, but came to realise that the songs she chose on this mixtape were also like islets – standout pieces of music amongst the waves. So put those headphones on, and head out to Alika's islet! — Song List: Aanshika Sharma - Taking a Pill (02:41 - 05:21) Purple Cassette - Got What You Need (06:52 - 09:24) Kiss Nuka - A Wilder Place (11:15 - 16:11) Kimaya Diggs - Bloom (17:58 - 21:48) Abhibyanjana Rubhi Thatal - Breezing Through (23:24 - 26:24) Dear Kokum - Back to Light (28:01 - 31:19) — Come be our friend: Facebook @maedinindia Instagram @maedinindia Twitter @maedinindia CREDITS: Host: Alika Gupta Instagram: @capefoxalix Twitter: @capefoxalix Audio Editor Post: Kartik Kulkarni Producer: Shaun Fanthome , Husein Haveliwala and Nikkethana Kamal
It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA approval for a pancreatic islet cell therapy to treat type 1, stem cell research moves ahead, big news from the ADA Scientific Sessions about what's next for medications like Mounjaro and a pill form of semaglutide. Dexcom announces a sensor for people with type 2 who don't use insulin, Libre moves ahead with Ketone monitoring and more. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange a nonprofit organization dedicated to improving outcomes for the entire T1D population. XX Big week of news following the 2023 ADA Scientific Sessions conference. What follows is just the tip of the information iceberg, so please follow the links in the show notes to much more. -- XX Top story though isn't from ADA – but a new FDA approval.. for a pancreatic islet cell therapy to treat type 1. It's called donislecel, developed from cadaver donors and giving as a single infusion straight into the liver. Immunosuppression is required to maintain cell viability, just as it is required to support a transplanted kidney or other organ. Approval was based on what seems to be a very small study – 30 people with type 1 who had hypoglycemic unawareness and who received between one and three infusions of donislecel. After one year, 11 people did not need to dose insulin.. 10 stayed that way for more than five years. But five people in the study were not able to stop dosing insulin at all. This method is different from what Vertex and Sernova are trying to do with stem cell therapy. https://www.medscape.com/viewarticle/993854 XX Vertex moves forward on their clinical trial of islet stem cell therapy. All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the year prior to treatment and required an average of 34.0 units of insulin per day. Following treatment, all six patients demonstrated endogenous insulin secretion, improved glycemic control as measured by HbA1c, improved time-in-range on continuous glucose monitoring, and reduction or elimination of exogenous insulin use. Two patient are completely insulin independent after one year – with an A1C of 5.3 compard to 8.6 at baseline.. the other 6.0 with a 7.6 at baseline – again the ”after” number is without taking insulin. As a result of these safety and efficacy data in Parts A and B, the independent data review committee has recommended moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions XX Sernova also reports good results with their cell pouch system. Five of the six patients who have completed implantation continue to experience insulin independence for periods ranging from six months to more than three years. The sixth patient only recently completed the protocol-defined islet transplants.. so no results yet. There is a second group testing a larger cell pouch. https://www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/ XX Big news from ADA about all of the type 2 and obesity drugs you've likely heard about.. here are some headlines: SURMOUNT-2 clinical trial evaluating tirzepatide – brand name Mounjaro - for weight loss in adults with obesity or overweight and type 2 diabetes. Average weight loss was 15.7% at the highest dose, with many other health benefits such as lower A1C levels; reduction in waist circumference, and body mass index; and improvements in cardiometabolic disease risk factors such as lipid levels, cholesterol, and blood pressure. That 15 percent weight loss was about 34 pounds and the a1c reduction for half of those in the study went down to 5.7 which is considered nondiabetic. Mounjaro is currently approved for type 2 and the FDA could approve Mounjaro regardless of diabetes status later this year. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval XX A study called PIONEER looks at oral semaglutides – some calling it the Ozempic pill. When compared to other anti-diabetic medications such as Jardiance, Januvia and Victoza, people taking the oral semaglutide say 1% or or more reduction of HbA1c compared to those treated with other anti-diabetic medicines. They also were more like to achieve a 5% or more reduction of body weight. Note: this was not a study comparing a semaglutide pill with the same type of injection. https://www.news-medical.net/news/20230607/Oral-semaglutide-outperforms-other-medications-in-type-2-diabetes-treatment-significantly-reducing-HbA1c-and-body-weight.aspx XX And look for two additional new drugs to treat obesity in the next few years.. orforglipron, is easier to use and to produce, and it will probably be cheaper than existing treatments. The second, retatrutide, has an unprecedented level of efficacy, and could raise the bar for pharmacological obesity treatment. Orforglipron and retatrutide both mimic hormones produced by the lining of the gut in response to certain nutrients. These hormones help to slow the passage of food through the digestive tract and lower appetite by acting on receptors in the brain — both effects that reduce people's desire to eat and help them to lose weight. Orfoglipron is a non-peptide molecule that researchers say is easy to produce and is a pill.. a lower price is anticipated for this one. Retratritude looks like it could help people lose even more weight than Mounjaro. https://www.nature.com/articles/d41586-023-02092-9 XX Dexcom announces a new product in the US – coming in 2024 – designed for people with type 2 who don't use insulin. This will be built on the G7 hardware, but with different software and a 15 day sensor. CEO Kevin Sayer also announced that the G7 will be able to share data direct to the apple watch https://www.businesswire.com/news/home/20230623025076/en/Global-Continuous-Glucose-Monitoring-Pioneer-Dexcom-Reveals-New-Plans-to-Bring-Sensing-Technology-to-Millions-More XX Abbott will partner with Weight Watchers - people who have been prescribed one of Abbott's FreeStyle Libre 14-Day or FreeStyle Libre 2 sensors and who are using the WeightWatchers diet plan to see their CGM data directly in the WeightWatchers app. This is also a study where Abbott will launch two pilot programs directed at using CGM data to help people with Type 2 diabetes adjust and manage their dietary habits, regardless of whether they're on insulin therapy. XX A little bit more news about Abbott's dual glucose and ketone sensor under development. Announced a last year's ADA, the company says it's moving forward through R&D Separately from the Type 2 CGM push, Taub also offered an update on the dual glucose ketone sensor that's currently under development at Abbott and that the company first announced at last year's ADA conference. The sensor will be aimed at catching rising ketone levels as early as possible to help avoid cases of diabetic ketoacidosis. An Abbot executive says – quote - “There's so much that we stand to learn about ketones because there hasn't been a continuous sensor for them before, so there's really very little we know about the evolution of ketones “ https://www.fiercebiotech.com/medtech/ada-abbott-pushes-widespread-cgm-use-type-2-diabetes-weightwatchers-ada-collabs XX Commercial XX Beta Bionics has received FDA 510(k) clearance for the compatibility of the Fiasp Pumpcart prefilled insulin cartridge with the iLet automated insulin-delivery system. The iLet is a bionic pancreas that fully automates 100% of all user insulin doses, providing users with the choice of three insulins, Novolog; Humalog; and Fiasp Pumpcart. The device eases diabetes management in everyday life and almost eliminates the expertise that has been required in the past to set up and manage a traditional insulin pump. In May 2023, Beta Bionics was awarded FDA approval for the iLet device. The iLet manages glucose levels with just a meal announcement and is paired with a Dexcom G6 Continuous Glucose Monitoring System for glucose readings. All that is required for set-up is the user's weight. While there is a need for carbohydrate awareness, no carb counting is necessary. Bolusing, correction factors, insulin-to-carb ratios, and pre-set basal rates are also unnecessary. Beta Bionics president and CEO Sean Saint said: “Beta Bionics has been working tirelessly to create an insulin delivery system that offers less burden and more convenience for the type 1 community. Since launching last month, the iLet bionic pancreas is now available and clinics and users are being trained on its simple design and easy management features. “When Fiasp Pumpcart prefilled cartridges are available, users will save time not having to manually fill cartridges and will have more choice for their diabetes management.” https://www.medicaldevice-network.com/news/beta-bionics-gains-fda-clearance-for-prefilled-insulin-cartridge/ XX Oura – the ring that tracks your sleep – will start sending info to three CGM info companies.. January, Supersapiens and Veri. All three of these companies provide software based off of the Libre CGM. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users' glucose levels and overall health. https://www.forbes.com/sites/andrewwilliams/2023/06/27/oura-smart-ring-can-be-used-to-help-monitor-blood-sugar/?sh=2520116c2b10 XX Just a fun fact here – there is a Facebook group called type 1 diabetics for 50 plus years. And it looks like this week they passed over 1500 members. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes
Check out “Heard on the Street” recorded during the Day 1 Poster session at Islet Study Group 2023. Hear from Manuj Bandral from TU Dresden as he discusses his poster: Islet clusters as mini-organs for diabetes therapies.
The Great Escape 2023.... three days of great music and great company.... with tracks by... Germein, Pacific Avenue, Reb Fountain, Mestizo, Bibi Club, The Heavy Heavy, Prima Queen, Islet, The Oozes, Moon Matess, Marina [...] The post PCP#793… The Great Escape 2023… appeared first on Pete Cogle's Podcast Factory.
On this episode, Jonathan is joined by Noel Morgan, Professor of Endocrine Pharmacology, University of Exeter, UK. The pair discuss Morgan's extensive research in diabetes, including his research on islet biology and signalling mechanisms regulating pro-inflammatory and anti-inflammatory processes in β-cells in Type 1 diabetes. They further discuss areas of research that excite and frustrate him, how we can change beliefs and behaviours associated with diabetes, and the future of diabetes research. Use the following timestamps to navigate the topics discussed in this episode: (00:00)-Introduction (02:00)-Morgan's origin story (03:30)-Experiences from Nashville, USA (06:00)-Islet biology (08:00)-Insulin secretion control (12:25)-Aetiology and differences between Type 1 and Type 2 diabetes (15:10)-The largest collection of rare pancreas samples in the world (17:50)-Different ‘types' of Type 1 diabetes (20:15)-Pro-insulin (22:35)-To B or not to B? (24:35)-Rituximab (26:00)-Dorothy Hodgkin Lecture (28:00)-The global obesity epidemic and changing behaviour (31:45)-The war on obesity (33:40)-A longer, unhealthy life? (34:45)-Exciting topics and immunotherapy (36:50)-Three wishes
CME credits: 0.50 Valid until: 30-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/predicting-type-1-diabetes-using-genetic-testing-or-islet-antibody-screening-are-we-there-yet/14286/ Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.=
CME credits: 1.25 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-immune-tolerance-induction-and-islet-encapsulation-new-hope-for-t1d/14642/ This program is designed to increase knowledge of current disease management strategies for severe hypoglycemia and impaired awareness of hypoglycemia (IAH) and create awareness on the emerging stem cell-based treatments for patients with type 1 diabetes (T1D).
CME credits: 1.25 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/critical-updates-on-islet-transplantation-and-clinical-trials-of-stem-cell-derived-islet-transplantation/14641/ This program is designed to increase knowledge of current disease management strategies for severe hypoglycemia and impaired awareness of hypoglycemia (IAH) and create awareness on the emerging stem cell-based treatments for patients with type 1 diabetes (T1D).
CME credits: 1.25 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/transplanting-islet-cells-how-do-we-measure-success/14639/ This program is designed to increase knowledge of current disease management strategies for severe hypoglycemia and impaired awareness of hypoglycemia (IAH) and create awareness on the emerging stem cell-based treatments for patients with type 1 diabetes (T1D).
Dar Voz a esQrever: Pluralidade, Diversidade e Inclusão LGBTI
O CENTÉSIMO QUADRAGÉSIMO SEXTO episódio do Podcast Dar Voz A esQrever
In this episode, we talk about an exciting experimental treatment for patients with type 1 diabetes called islet cell transplantation. Host Aaron Lohr talks with David Baidal, MD, assistant professor of medicine at the University of Miami Miller School of Medicine. This episode is made possible through an unrestricted, educational grant from Vertex Pharmaceuticals. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast.
In this episode, we talk about an exciting experimental treatment for patients with type 1 diabetes called islet cell transplantation. Host Aaron Lohr talks with David Baidal, MD, assistant professor of medicine at the University of Miami Miller School of Medicine. This episode is made possible through an unrestricted, educational grant from Vertex Pharmaceuticals. Show notes are available at https://www.endocrine.org/podcast/enp61-islet-cell-transplantation-for-diabetes — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast
In this episode, we talk about an exciting experimental treatment for patients with type 1 diabetes called islet cell transplantation. Host Aaron Lohr talks with David Baidal, MD, assistant professor of medicine at the University of Miami Miller School of Medicine. This episode is made possible through an unrestricted, educational grant from Vertex Pharmaceuticals. Show notes are available at https://www.endocrine.org/podcast/enp61-islet-cell-transplantation-for-diabetes — for more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast
This is a re-posting of Episode 55 due to audio problems with the original posting. In this episode, we talk about a potential marker to help identify youth with type 1 diabetes, islet autoimmunity, and insulin deficiency. This new research was presented at ENDO 2022, and the abstract is titled, "Elevated Serum IgA at Onset of Type 1 Diabetes in Children." Host Aaron Lohr speaks with one of the authors, Amruta Thakkar, MD, of Texas Children's Hospital and the Baylor College of Medicine. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast.
Sete novas confirmações para o Super Bock em Stock; Surma lança novo single «Islet»; Começa hoje o primeiro fim-de-semana do Amplifest no Hard Club, no Porto.
It's in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant. This was in rats.. but they achieved glycemic control without insulin injections and without immunosuppressive drugs for four months. AdoShell Islets is an immuno-protective synthetic biomaterial that secrets insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host's immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets. These researchers are optimistic that their unique approach can be translated from one species to another. https://www.labiotech.eu/trends-news/adocia-implants-diabetes/ XX Can starting a closed loop system right away help keep kids with type 1 in the honeymoon stage longer? New study says.. probably not. The latest findings are from the Closed Loop From Onset in Type 1 Diabetes (CLOuD) trial, a multicenter, open-label, parallel-group, randomized study, published online September 7 in the New England Journal of Medicine by Charlotte K. Boughton, PhD, and colleagues. In CLOuD, 97 youths aged 10-17 years were randomized to hybrid closed-loop therapy or standard insulin therapy (control) within 21 days of type 1 diabetes diagnosis. I found this a bit confusing, in the standard insulin therapy groups, participants could switch to insulin pump therapy or use flash or continuous glucose monitoring (CGM) or approved closed-loop systems if clinically indicated. So this isn't comparing an AID system to MDI. At 12 months, there were no differences after a mixed-meal tolerance test, with levels declining in both groups and dropping further by 24 months. Interestingly, they said glycemic control didn't differ significantly between the two groups. https://www.medscape.com/viewarticle/980356 XX Moving closer to a non-invasive way to measure blood glucose. The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute. This looks to be about the size of a Libre 3 or Dexcom G7.. It's said to have smart alarms and remote monitoring capability and just sticks on the skin. The MARD is 10 point 4, which is less accurate than CGMs on the market now, but much better than any other noninvasive device to make it this far. In addition to measuring blood glucose the makers say it can measure oxygen levels, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. Pivotal clinical study later this year and then the say they'll submit for European approval. https://www.med-technews.com/news/latest-medtech-news/glucorx-and-cardiff-university-to-bring-out-non-invasive-con/ XX RESEARCHERS in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes, before children develop symptoms or need insulin. They're offering a finger stick test when children have their pre-school vaccination. Very small start, only 60 kids, but these researchers say with a recent, more accurate test to check for markers early on, they hope to find more children before DKA sets in. https://www.oxfordmail.co.uk/news/20977659.oxford-scientists-launch-study-early-markers-type-1-diabetes-children/ XX The first Randomized Controlled Trial on open source automated insulin delivery (AID) is now published in a peer-reviewed medical journal. Big news for and from the we are not waiting crowd. The CREATE Trial evaluated the efficacy and safety of an open-source system using the OpenAPS algorithm in a modified version of AndroidAPS. This study included children and adults and found that across all ages, time in range was 14 percent higher than those who used commercial hybrid closed loop systems. There's more to it, and I”ll link it up, but this study concluded that a widely used open-source AID solution, works and is safe. Congrats to Dana Lewis and all the researchers involved. https://diyps.org/2022/09/07/nejm-publishes-rct-on-open-source-automated-insulin-delivery-openaps-algorithm-in-androidaps-in-the-create-trial/ XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Medtronic is waiting for FDA clearing of the new 780G.. already approved in Europe. New study results published in The Lancet Diabetes & Endocrinology, Medtronic announced Thursday put the AID pump up against multiple daily injections plus CGM. Small study, 82 people, all with an A1C over 8. After using the 780G for six months, the group saw a reduction of 1.4 percent in their levels with a quarter of that group dropping their A1C below 7. None of the MDI group dropped to that level. Time in range saw most improvement overnight. The MiniMed 780G system has been cleared in Europe since 2020. Medtronic submitted it to the FDA for U.S. approval in the spring of 2021 but is still awaiting a decision, slowed down by the roadblocks caused by a late 2021 warning letter from the agency that called out quality control issues at the California headquarters of its diabetes business. https://www.fiercebiotech.com/medtech/medtronics-new-minimed-insulin-pump-adds-27-boost-time-range-study-finds XX Change at one of the top posts at Dexcom. Jake Leach moves from Chief Technology Officer to Chief operating officer. He's been at the company since 2004 to work on the first commercial Dexcom CGM system. He's been a frequent guest of the show and we hope that continues. https://www.businesswire.com/news/home/20220831005236/en/DexCom-Promotes-Jake-Leach-to-Chief-Operating-Officer XX Next week we're looking ahead to the New York City Marthong. Beyond Type 1 puts together a gret team each year and I'm taking to one of the runners. He's also nabbed a spot in the world series of poker – which do you think is tougher on his type 1 diabetes? This past episode is all about Omnipod 5 – a panel of people who've sued it for a few weeks now.. and the director of medical affairs to answer your questions. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
In this episode, we talk about a potential marker to help identify youth with type 1 diabetes, islet autoimmunity, and insulin deficiency. This new research was presented at ENDO 2022, and the abstract is titled, "Elevated Serum IgA at Onset of Type 1 Diabetes in Children." Host Aaron Lohr speaks with one of the authors, Amruta Thakkar, MD, of Texas Children's Hospital and the Baylor College of Medicine. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast
In this episode, we talk about a potential marker to help identify youth with type 1 diabetes, islet autoimmunity, and insulin deficiency. This new research was presented at ENDO 2022, and the abstract is titled, “Elevated Serum IgA at Onset of Type 1 Diabetes in Children.” Host Aaron Lohr speaks with one of the authors, Amruta Thakkar, MD, of Texas Children's Hospital and the Baylor College of Medicine. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast
In this episode, we talk about a potential marker to help identify youth with type 1 diabetes, islet autoimmunity, and insulin deficiency. This new research was presented at ENDO 2022, and the abstract is titled, “Elevated Serum IgA at Onset of Type 1 Diabetes in Children.” Host Aaron Lohr speaks with one of the authors, Amruta Thakkar, MD, of Texas Children's Hospital and the Baylor College of Medicine. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast
Top stories In the News this week, United Healthcare announces changes to how they cover insulin for some, a new study looks at CGM use in people with type 2 over the age of 65, another company begins islet cell clinical trials, a new tool to treat diabetic neuropathy pain, gestational diabetes is on the rise, and more. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story.. United Healthcare says it will have no “out of pocket” expenses for insulin starting January first. It's doing the same for other critical drugs like glucagon, epinephrine and albuterol. Looking into this a bit more, though, it's not the boon it first seems. This only covers certain eligible patients. Stat news says about a quarter of United Healthcare's patients will qualify but I saw a few commentators say it could actually be less than 5-percent. UnitedHealth Group shared that it earned $5.1 billion in profit for the second quarter of 2022. https://kstp.com/kstp-news/top-news/united-healthcare-says-no-out-of-pocket-expenses-for-insulin/ XX Not too surprising but a good study about people with type 2 using CGMs. This was for people using basal insulin only and over 65 years old. They found when given a CGM, their A1Cs went down an average of 1 full point with fewer lows. These are the kinds of studies that may seem obvious to us but that are needed to show insurers they need to cover. https://www.liebertpub.com/doi/10.1089/dia.2021.0494 XX New device approved to treat pain associated with diabetic peripheral neuropathy. The DyAnsys' First Relief system is set behind the ear – its an adhesive, nothing surgical. It features three small, acupuncturelike needles that reach through the skin behind the ear to access the nervous system. Once in place, the device continuously emits low-level electrical pulses over the course of several days at a time; the FDA cleared the system for repeated treatments spanning up to eight weeks. https://www.fiercebiotech.com/medtech/fda-clears-wearable-neurostimulator-dyansys-treat-pain-diabetic-nerve-damage XX Another company having success with islet cell transplants. ProtoKinetix announced they're completely safety objectives and will start phase 1 clinical trials of their molecule PKX-001. Not much to report here yet, but I didn't want to news of the Vertex/Viactye merger to over shadow that there are other efforts going on here. https://www.businesswire.com/news/home/20220720005086/en/ProtoKinetix-Successfully-Completes-Phase-1-Clinical-Trials-for-the-Treatment-of-Type-1-Diabetes-in-Islet-Cell-Transplants XX Roche and Insulet settle their lawsuit.. this was a patent issue and both companies were suing each other. Insulet will give Roche 20-million dollars and Roche has agreed not to sue Insulet for five years. This was set to go to trial next week. https://seekingalpha.com/news/3855728-insulet-to-pay-20m-to-settle-patent-lawsuit XX Gestational diabetes is on the rise, climbing 30% between 2016 and 2020, according to a new study by the Centers for Disease Control and Prevention.The CDC analysis showed that cases increased 13% during the first year of the pandemic alone, a much larger spike than the previous annual increases of about 5%. Experts say that the sharp increase during Covid may be because the disease accelerated people's adoption of a sedentary lifestyle and led to pandemic-related physical and emotional stress. experts are concerned outcomes in 2021 may be worse, when Covid hit harder. If anything, the authors and experts said, the new finding is likely an undercount. Relying on birth certificate data, which the CDC study did, can miss cases that are not captured by a physician on those forms. “If you think about it, somebody who's doing 20 deliveries in a night, or ten deliveries in a night, is just kind of trying to get those reports and certificates out there,” said Morgan. “They're not paying as much attention to some of those details.” https://www.statnews.com/2022/07/20/as-diabetes-during-pregnancy-grows-more-common-experts-point-to-a-need-for-preventive-care/ XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX /about-us/ XX Next week on the podcast I'm talking to Sebastien Sasseville who recently completey the absolutely exhausting sounding Race Across America. We'll talk about how you manage type 1 – and everything else – when you're spending more than 20 hours a day on a bike for 12 days! The long format episode out right now is with the folks at Diabetes Wise – that's a website to help you choose diabetes technology.. they've added information for doctors – this may help you educate your heathcare providers on why you want the pump or cgm system that you do.. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
Broadcast on Bilibili 22.5.2 for KAKUSATSU SHOUJU 2 release party 1. Islet - 流転 (from ASTER) 2. Mameyudoufu - I STILL Don't Know What I'm Doing (from Stream Friendly 01) 3. Juggernaut. - Gehirn (from Gehirn EP) 4. Silentroom Arranged by Sobrem - Variations on Silent Rhapsody (from In My Heart) 5. Sennzai - UNINHIBITED (from VTTRACT) 6. Frums - Polaris (from The Unattended) 7. お嬢様DTMers - Noblesse Oblige (from お嬢様DTMer) 8. qumogi - Cell Dust (from Come to a Fall) 9. EBIMAYO - Spacewalk (from GOODBOUNCE EX) 10. ぽすとん。 - Ivy (from click) 11. 藍月なくる - Codependence (from Indigrotto) 12. 棗いつき - アノニマスビーツ (from 覚醒) 13. KO3 - Can't you feel it feat. mami (from encore -Emotional Vocal POP 03) 14. Mameyudoufu - 才能 feat. ANNE (from encore -Emotional Vocal POP 03) 15. Capchii - 満身創痍 (from VOCALO EDM10 SWEET) 16. IOSYS - ScarletPoliceonGetthoPatrol (from スカーレット警察・総集編 春の特別警戒スペシャル) 17. Dariush Gee - How Can I Hate (Jason Little Remix) (from J-SCHRANZ 5) 18. M-Project - Dooms Day (from J-SCHRANZ 5) 19. Nasvy - Tokyo Traffic (Hiy EUROBEAT Remix '22) (from インフィニティ・オトゲイズム！) 20. KikKuU - DON'T FORGET TO DANCE (from VOCALO EDM10 HEAVY) 21. mitei - Breaking (from Lost) 22. OZIGIRI - サマーエンジェルパラノイア (from IMMORTAL HARDCORE!!!! VOL.6 -Black Out-) 23. you - Glider (from SSSI: Sharp Slash Shark Identity) 24. ikaruga_nex - Martyr of thunder (from SSSI: Sharp Slash Shark Identity) 25. P*Light - Chu★Chu★Chu (from Bright Colors 6 ) 26. 座頭景; 覆面忍者 - 7L SUNDAY (feat. 潮成実) (from 8 File) 27. Pastel Tone Music - Emerged (from Fluffy◊Dreamy)
Tik Tok Taught Me Minisode! Related Tik Toks:https://www.tiktok.com/@checkoutjon/video/7072442778860571950?lang=en&ishttps://www.tiktok.com/@ijorgealvarez/video/6980778621921201414?lang=en&isLet's Connect! https://lnk.bio/bigquiqui
Contrarian Investing is a termcommonly heardin the investing industry so its important you know what it isLet’s go!
In this episode, we review the high-yield topic of Islet Cell Tumors from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
What's the difference between Type 1 and Type 2 diabetes? How can you reduce your risk? And what's the hype about the diabetes connection to obesity and dementia? In this episode of NewsMD's podcast, "Health Fusion," Viv Williams gets the answers from two University of Minnesota experts.
© 2020-2025 Ivy Podcast Discovery LLC
